Skip to main content

Table 1 Potential neoantigens derived from various genetic variations for AML

From: Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia

Gene name

Mutated position

neopeptide

HLA restriction

References

Gene fusion

    

CBFB-MYH11

/

REEMEVHEL

B*40:01

[53]

PML-RARA

/

NSNHVASGAGEAAIETQSSSSEEIV

DR*11

[56]

DEK-CAN

/

TMKQICKKEIRRLHQY

DR*53; DR*9

[101]

Indels

    

NPM1

283–291

AIQDLCLAV

A*02:01

[18, 20]

283–291

AIQDLCVAV

A*02:01

[18, 20]

289–297

LAVEEVSLR

A*02:01

[61]

290–298

AVEEVSLRK

A*02:01

[61]

288–296

CLAVEEVSL

A*02:01

[62]

FLT3-ITD

/

YVDFREYEYY

A*01:01

[68]

Non-synonymous point mutations

IDH1

R132H

GWVKPIIIGHHAYGDQYRAT

DRB1*0101

[74]

KRAS

G12D

GADGVGKSA

C*08:02

[83]

G12D

GADGVGKSAL

C*08:02

[83]

G12D

VVVGADGVGK

A*11:01

[102]

G12V

VVVGAVGVGK

A*11:01

[102]

TP53

R175H

HMTEVVRHC

A*02:01

[89, 94]

R175H

YKQSQHMTEVVRHCPHHERCSDSDG

Class II

[89]

R175H

VVRHCPHHERCSDSD

DRB1*13:01

[89]

R175H

QHMTEVVRHCPHHER

DRB1*13:01

[89]

Y220C

RNTFRHSVVVPCE

DRB1*04:01

[89]

Y220C

VVPCEPPEV

A*02:01

[89]

Y220C

NTFRHSVVVPCEPPE

DRB3*02:02

[89]

G245S

HYNYMCNSSCMGSMN

DRB3*02:02

[89]

R248Q

YMCNSSCMGGMNQRPILTIITLEDS

Class I and II

[89]

R248W

SSCMGGMNWR

A*68:01

[89]

R248W

SCMGGMNWRPILTII

DRB1*02:01

[89]

R248W

FEVRVCACPGRDWRTEEENLRKKGE

Class II

[89]

G245S

HYNYMCNSSCMGSMN

DRB3*02:02:01

[90]

Y220C

NTFRHSVVVPCEPPE

DRB3*02:02:01

[90]

P190L

ALPQHLIRV

A*0201

[91]

R267P

LLGPNSFEV

A*0201

[91]

A161T

RVRAMTIYKQ

A*1101

[93]

Splicing variants

SF3B1

R625C/H/L/S

LLIRWQHFL

A*0201

[99]

AALPILFQV

A*0201

[99]

ALLLQLFTL

A*0201

[99]

ALLPGLPAA

A*0201

[99]

RLPGVLPRA

A*0201

[99]